KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Capital Employed (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Capital Employed for 14 consecutive years, with 0.28% as the latest value for Q4 2024.

  • On a quarterly basis, Return on Capital Employed rose 8.0% to 0.28% in Q4 2024 year-over-year; TTM through Dec 2024 was 0.28%, a 8.0% increase, with the full-year FY2024 number at 0.31%, up 11.0% from a year prior.
  • Return on Capital Employed was 0.28% for Q4 2024 at Halozyme Therapeutics, up from 0.2% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 1.1% in Q4 2020 to a low of 0.16% in Q4 2022.
  • A 5-year average of 0.37% and a median of 0.28% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 128bps in 2020, then tumbled -84bps in 2021.
  • Halozyme Therapeutics' Return on Capital Employed stood at 1.1% in 2020, then crashed by -76bps to 0.27% in 2021, then crashed by -42bps to 0.16% in 2022, then rose by 28bps to 0.2% in 2023, then surged by 42bps to 0.28% in 2024.
  • Per Business Quant, the three most recent readings for HALO's Return on Capital Employed are 0.28% (Q4 2024), 0.2% (Q4 2023), and 0.16% (Q4 2022).